rel
short
period
time
rnai
shown
cultur
cell
efficaci
variou
virus
includ
respiratori
syncyti
viru
rsv
influenza
viru
polioviru
hepat
c
viru
hcv
hiv
varieti
sirna
also
report
effect
interrupt
viral
infect
two
sirna
strategi
consid
hiv
first
target
essenti
viral
gene
second
target
cellular
gene
requir
hiv
replic
tabl
date
hiv
sequenc
target
includ
structur
gag
gene
infect
factor
vif
nef
tat
rev
env
tar
rna
instanc
sequencespecif
silenc
viral
rna
transient
suppress
hiv
replic
period
day
singl
round
infect
cultur
cell
achiev
howev
import
note
virionassoci
genom
rna
infect
cell
appear
resist
rnaimedi
degrad
find
argu
goal
prevent
genesi
integr
proviru
use
sirna
one
target
cellular
factor
requir
earli
step
replic
rather
viral
sequenc
sirna
direct
sever
relev
cellular
factor
inde
test
antivir
efficaci
includ
sirna
target
viral
entri
eg
sirna
hiv
coreceptor
chemokin
cc
motif
receptor
chemokin
cxc
motif
receptor
hiv
transcript
eg
sirna
cyclin
cyclindepend
kinas
suppressor
homolog
export
rna
nucleu
cytoplasm
eg
sirna
rpa
interact
protein
rpain
hrip
srcassoci
protein
mitosi
viru
assembl
bud
eg
target
lyst
interact
protein
cellular
protein
involv
multivesicular
bodi
format
target
tumor
suscept
gene
also
call
vacuolar
proteinsort
protein
involv
endocyt
traffick
cellular
protein
use
replic
peptidylprolyl
isomeras
cyclophilin
ra
oncogen
famili
member
mani
exampl
point
instead
directli
introduc
sirna
duplex
cell
effect
transient
mani
case
rnai
express
use
dna
plasmid
express
short
hairpin
rna
shrna
recogn
cell
dicer
enzym
remov
hairpin
loop
shrna
molecul
process
sirna
counterpart
current
myriad
system
avail
express
shrna
eg
control
rna
polymeras
iii
promot
rna
polymeras
ii
cmv
promot
sever
vector
system
eg
adenovir
lentivir
vector
allow
longterm
silenc
even
nondivid
cell
notori
mutabl
viru
effect
antivir
drug
base
sequenc
hybrid
must
take
account
mutat
sequenc
easili
inde
escap
sirna
nucleotid
mutat
exampl
da
et
al
observ
sirna
target
nef
rapidli
elicit
emerg
sirnaresist
virus
point
mutat
nef
gene
altern
delet
sirna
recognit
site
also
allow
viru
evad
restrict
moreov
evid
undergo
nucleotid
substitut
induc
altern
rna
fold
thu
shield
previous
target
sequenc
access
sirna
minim
mutat
escap
hiv
one
strategi
simultan
use
multipl
sirna
target
discret
sequenc
likelihood
singl
viral
rna
molecul
would
mutat
target
sequenc
becom
increasingli
small
number
target
escal
multitarget
strategi
aid
comput
model
predict
might
evolv
cell
express
multipl
antivir
sirna
anoth
way
circumv
viral
escap
target
viru
sequenc
cellular
gene
need
exampl
dualspecif
shrna
effici
inhibit
viral
entri
simultan
target
cell
surfac
receptor
report
addit
evolv
sirnaescap
mutat
virus
also
encod
suppressor
factor
attenu
cell
rnai
respons
much
remain
elucid
appear
multifacet
way
suppress
cell
rnai
machineri
viral
tat
protein
appear
work
protein
suppressor
rnai
addit
viral
rna
tar
also
use
suppressor
rnai
sirnabas
therapi
virus
use
contempl
one
need
consid
strategi
address
virusencod
rnai
suppressor
despit
viral
encod
suppressor
ampl
evid
rnaimedi
inhibit
replic
possibl
suppressor
either
synthes
late
amount
small
counter
effect
preexist
sirna
shrna
sirna
machineri
use
eukaryot
cell
use
process
class
endogen
small
rna
call
microrna
mirna
mirna
import
regul
least
cellular
gene
includ
involv
develop
signal
transduct
apoptosi
cell
prolifer
tumorigenesi
date
human
mirna
describ
like
discov
see
mirna
databas
mechan
mirna
action
relev
mirna
infect
review
elsewher
elabor
need
emphas
fact
share
factor
shrna
sirna
mirna
process
satur
entiti
mirna
essenti
cellular
metabol
viabil
machineri
mirna
genesi
divert
handl
exogen
sirna
shrna
dearth
mirna
potenti
manifest
cellular
toxic
hitherto
unexpect
find
inde
demonstr
recent
studi
vivo
overexpress
shrna
mice
studi
sever
liver
toxic
death
mice
occur
within
week
shrna
treatment
explan
fatal
satur
shrna
pathway
normal
use
liver
process
mirna
henc
high
shrna
express
mous
liver
overwhelm
export
pathway
ie
need
transport
precursor
mirna
nucleu
cytoplasm
interrupt
proper
transport
mirna
precursor
led
reduc
level
matur
mirna
result
cellular
toxic
apart
problem
pathway
satur
offtarget
effect
sirna
rais
addit
concern
ontarget
effect
eman
perfect
complementar
guiderna
target
mrna
ie
match
nucleotid
basepair
offtarget
effect
aris
nucleotid
fortuit
basepair
sirna
mrna
consid
way
particular
sirna
could
potenti
suppress
express
intend
target
sever
unintend
mrna
offtarget
phenomenon
signific
drawback
sirna
envis
vivo
use
human
drug
one
anticip
method
modif
minim
offtarget
hybrid
would
need
greatli
improv
enabl
sirna
drug
develop
anoth
unwelcom
advers
effect
sirna
use
potenti
inappropri
elicit
interferon
inflammatori
cytokin
normal
rna
duplex
shorter
nucleotid
length
would
expect
trigger
interferonlink
protein
kinas
r
pathway
howev
recent
found
gurich
sequenc
tolllik
receptor
tlr
immunostimulatori
motif
trigger
interferon
respons
even
present
duplex
shorter
nucleotid
minim
nonspecif
interferon
respons
judici
care
must
exercis
sequenc
design
sirna
drug
recent
optim
regard
possibl
sirna
drug
aris
studi
indic
intraven
inject
sirna
direct
fa
protect
mice
liver
injuri
fibrosi
two
model
autoimmun
hepat
find
intranas
administr
separ
sirna
protect
mice
rsv
infect
rhesu
macaqu
sar
coronaviru
infect
sirna
applic
mous
genit
tract
also
found
protect
lethal
herp
simplex
viru
type
infect
preliminari
posit
find
prompt
phase
studi
initi
human
date
three
clinic
trial
complet
human
show
signific
sirna
toxic
sirna
current
clinic
investig
two
diseas
agerel
macular
degener
amd
caus
overexpress
vascular
endotheli
growth
factor
vegf
respiratori
infect
caus
rsv
time
sirna
drug
outlin
sever
issu
uniqu
target
viral
gene
appli
target
cellular
gene
howev
question
relev
sirna
applic
best
deliv
sirna
virusinfect
cell
regard
sever
method
consid
exampl
hcv
infect
procedur
coupl
sirna
cholesterol
allow
effici
target
hepatocyt
cell
preferenti
infect
viru
elsewher
novel
strategi
use
antibodymedi
sirna
deliveri
propos
cell
whether
biochem
deliveri
techniqu
distribut
sirna
effect
vivo
compart
await
verif
also
virusbas
approach
deliv
shrna
howev
type
gene
therapi
approach
rais
issu
relat
biosafeti
major
focu
cell
use
lentivir
vector
abil
infect
nondivid
cell
rest
tcell
macrophag
progenitor
hematopoiet
cell
cell
exampl
progress
vector
design
includ
induc
vector
antirev
cassett
shown
effect
inhibit
hiv
replic
doxycyclinedepend
lentivector
go
forward
major
challeng
perfect
vector
wholli
silent
shrna
express
unless
specif
trigger
infect
despit
optim
deliveri
sirna
shrna
cell
abil
virus
mutat
escap
rnai
significantli
daunt
problem
multimod
approach
may
adopt
order
minim
viral
escap
exampl
shrna
target
rev
use
time
tran
dominantneg
rev
protein
inhibit
infect
test
tissu
cultur
protect
shrnatransduc
human
hematopoiet
cell
infect
shrnaresist
viru
emerg
infect
period
separ
combin
three
differ
rna
technolog
propos
therapi
strategi
simultan
use
shrna
rev
tat
protein
tar
rna
decoy
suppress
transcript
ribozym
attenu
coreceptor
cell
surfac
tissu
cultur
approach
protect
stem
cell
infect
without
emerg
viral
escap
mutant
principl
develop
sirna
drug
sound
compel
practic
challeng
longterm
expressiondeliveri
sirna
shrna
propens
viru
escap
evad
rnai
offtarget
toxic
issu
real
difficult
figur
realiz
efficaci
practic
sirna
drug
requir
technolog
breakthrough
much
addit
time
effort
